Biomarkers for melanoma
AssigneeThe Johns Hopkins University
InventorsRhoda Myra Alani, Byungwoo Ryu
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods of determining melanoma status in a subject. The invention also relates to kits for determining melanoma status in a subject. The invention further relates to methods of identifying biomarker for determining melanoma status in a subject.
Claims10
A product comprising isolated biomarkers bound to a biochip array, wherein the biomarkers are insulin-like growth factor binding protein 3, IL-6, and CXCL1.
A product comprising purified biomarkers bound to a microarray comprising addressable locations using a biospecific capture reagent, wherein the biomarkers are insulin-like growth factor binding protein 3, IL-6, and CXCL1.
A kit for the diagnosis of melanoma, comprising:
- purified biomarkers bound to a microarray comprising addressable locations using an adsorbent or capture reagent, wherein the purified biomarkers are insulin-like growth factor binding protein 3, IL-6, and CXCL1, and written instructions for
- isolating a biomarker from a test sample comprising affected tissue isolated from a subject;
- contacting the biomarker with the adsorbent or capture reagent such that the biomarker is retained;
- detecting the differential presence of said biomarker in the test sample relative to a reference;
- and
- correlating measurement of the biomarker with melanoma status.
A biochip array comprising isolated biomarkers, wherein the biomarkers are insulin-like growth factor binding protein 3, IL-6, and CXCL1.
A biochip array having addressable locations comprising isolated biomarkers, wherein the biomarkers are insulin-like growth factor binding protein 3, IL-6, and CXCL1.
A product comprising isolated biomarkers bound to a bead by a biospecific capture reagent, wherein the biomarkers are insulin-like growth factor binding protein 3, IL-6, and CXCL1.
A biochip comprising isolated biomarkers, wherein the biomarkers are insulin-like growth factor binding protein 3, IL-6, and CXCL1.
Dependencies are inferred from the claim text.